We report a retrospective clinicopathologic study of 108 primary thyroid gland lymphomas (PTLs), classified using the REAL and proposed WHO classification schemes. The patients included 79 women and 29 men, with an average age of 64.3 years. All patients presented with a thyroid mass. The PTLs were classified as marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue (MALT) or MZBL (n ‫ס‬ 30), diffuse large B-cell lymphoma (DLBCL) with MZBL (n ‫ס‬ 36), DLBCL without MZBL (n ‫ס‬ 41), and follicle center lymphoma (FCL; n ‫ס‬ 1). Excluding the FCL, features of lymphomas of MALT-type were identified in all groups, despite a follicular architecture in 23% of cases. Lymphocytic thyroiditis (LT) was identified in 94%. Ninety-one percent of patients presented with stage IE or IIE disease, whereas 69% had perithyroidal soft tissue infiltration. All patients were treated with surgical excision followed by adjuvant therapy (76%): chemotherapy (15%), radiation (19%), or a combination of radiation and chemotherapy (42%). Disease-specific survival was 82% at last follow up (mean, 82.8 mos) and 79% at 5 years. Statistically, stages greater than IE, presence of DLBCL, rapid clinical growth, abundant apoptosis, presence of vascular invasion, high mitotic rate, and infiltration of the perithyroidal soft tissue were significantly associated with death with disease. No patients with MZBL or stage IE disease died with disease. In summary, PTLs typically occur in middle-to older-aged individuals as a thyroid mass, with a predilection for females. Despite their histologic heterogeneity and frequent simulation of other lymphoma subtypes, virtually all PTLs are lymphomas of MALT-type arising in the setting of LT. Mixed DLBCL and MZBL are common. Overall, PTLs have a favorable outcome with appropriate therapy, but prognosis depends on both clinical stage and histology. MZBL and stage IE tumors have an excellent prognosis, whereas tumors with a large cell component or DLBCL or stage greater than IE have the greatest potential for a poor outcome. Primary thyroid gland lymphomas (PTLs) are uncommon tumors that have been estimated to represent approximately 5% of all thyroid neoplasms 73 and 2.5% to 7% of all extranodal lymphomas. 10, 24, 59 Studies have shown that PTLs typically occur in middle-to older-aged women and arise in the setting of autoimmune thyroiditis (lymphocytic thyroiditis, Hashimoto's disease). The relative risk of a patient with lymphocytic thyroiditis developing lymphoma has been estimated to be 40 to 80 times greater than in the general population 29, 43, 59 and to take, on average, 20 to 30 years to develop after the onset of lymphocytic thyroiditis.
Primary thyroid gland lymphomas (PTLs) are uncommon tumors that have been estimated to represent approximately 5% of all thyroid neoplasms 73 and 2.5% to 7% of all extranodal lymphomas. 10, 24, 59 Studies have shown that PTLs typically occur in middle-to older-aged women and arise in the setting of autoimmune thyroiditis (lymphocytic thyroiditis, Hashimoto's disease). The relative risk of a patient with lymphocytic thyroiditis developing lymphoma has been estimated to be 40 to 80 times greater than in the general population 29, 43, 59 and to take, on average, 20 to 30 years to develop after the onset of lymphocytic thyroiditis. 59 In the past, PTLs have been classified using a variety of different terms because of the use of older histologic classifications, implying variable clinical behavior. 3, 5, 9, 13, 19, 23, 24, 30, 41, 42, 45, 48, 51, 52, 54, 63, 64, 70, 71, 74, 75, 77, 80 There is a better understanding of the concept of mucosaassociated lymphoid tissue (MALT) and recognition of the lymphomas that can arise from MALT because of the initial description by Isaacson and Wright. 35 In light of the MALT concept, certain authors think PTLs represent a single clinicopathologic entity: MALT lymphoma. 3, 36 In the Revised European-American Classification of Lymphoid Neoplasms (REAL) 27 and in the proposed World Health Organization (WHO) Classification for Neoplastic Diseases of the Lymphoid Tissues, 40 these distinct lymphoid tumors are included under the term "marginal zone B-cell lymphoma of MALT-type (MZBL)."
Whereas large cell transformation of MZBL (mixed DLBCL and MZBL) is recognized and has been reported in the thyroid 34, 45, 59, 69 and studied in other extranodal sites, 17, 22, 30, 46, 60, 61, 66 its characterization, frequency, and effect on clinical behavior remains unclear in the thyroid gland. Furthermore, there are no large, long-term clinicopathologic studies of PTLs using the MALT concept and the most recent lymphoma classification schemes (REAL and proposed WHO). Therefore, we undertook a retrospective study of 108 PTLs using current concepts to characterize the clinical, histomorphologic, immunophenotypic, and molecular characteristics of PTLs.
MATERIALS AND METHODS
One hundred eight cases of PTL, seen in consultation from 1985 to 1993, were retrieved from the files of the Endocrine Registry at the Armed Forces Institute of Pathology, Washington, DC. They were selected from a total of 170 cases (2.4% of 7083 benign and malignant primary thyroid gland neoplasms seen in consultation during the same period). The authors defined PTLs as lymphomas that presented primarily as thyroid gland tumors. Cases were excluded if there was inadequate clinical history and follow up, a lack of hematoxylin and eosin (H&E)-stained sections, insufficient material for immunohistochemical analysis, or a history of lymphoma. Ninety-four cases were obtained from civilian sources, including university medical centers and foreign contributors, 11 cases from military hospitals, and three cases from Veterans Administration Medical Centers.
Materials were supplemented by a review of surgical pathology and operative reports, cancer registry records, and written questionnaires or oral communication with the treating physician(s). Follow-up information included patients' demographics, symptoms at presentation, radiographic studies, clinical and surgical staging of the lymphoma, treatment modalities, and the current status of the disease and patient.
The lymphomas were classified with the aid of established criteria, recent studies, and the REAL and proposed WHO classifications. 27, 31, 40 They were evaluated for features of MALT or lymphomas of MALT-type, including lymphoepithelial lesions (LEL), monocytoid B-cells, centrocyte-like cells, plasma cells, abnormal cytoplasmic immunoglobulin accumulations, Dutcher bodies, and reactive follicles with or without colonization by lymphoma ("follicular colonization"). Additional features assessed were presence or absence of abundant apoptosis (more than four apoptotic cells per high-power field [HPF] using the 40× objective), tumor necrosis, vascular invasion (infiltration of neoplastic cells into the wall of any thyroidal vessel [artery, vein, or lymphatic]), and extension into the perithyroidal adipose tissue and/or skeletal muscle. Fibrosis was graded semiquantitatively as mild (thin bands or small microscopic foci of fibrosis on high-power magnification [40× objective]), moderate (broad bands of fibrosis on intermediate magnification [20× objective]), and severe (large areas of sclerosis replacing the thyroid architecture on low-power magnification [10× objective]). Mitotic activity was rated as low (less than 10 mitotic figures/10 HPF) or high (greater than 10 mitotic figures/10 HPF), using the 40× objective. Diffuse large cell lymphoma was defined as a lymphoma or areas within a small cell lymphoma that were comprised of large lymphoid cells that "sheeted out" in a diffuse manner. Increased, scattered, single, large immunoblasts or Reed-Sternberg-like cells in a small cell lymphoma or a predominance of large atypical cells in the follicles of a small cell lymphoma were not considered indicative of a large cell lymphoma. All cases were investigated for the presence of lymphocytic thyroiditis, defined in this study as reactive lymphocytic or lymphoplasmacytic infiltrates in the thyroid parenchyma with formation of lymphoid aggregates and fibrosis. The presence of follicles with germinal center formation and oxyphilic change of the follicular epithelium was not required for this designation. Other thyroid abnormalities were also documented.
With the aid of Musshoff's modification of the Ann Arbor staging system, 16 PTLs were staged as follows: IE: PTLs with or without extension into the perithyroidal soft tissue; IIE: PTLs with involvement of lymph nodes on the same side of the diaphragm; IIIE: PTLs with involvement of lymph nodes on both sides of the diaphragm and/or spleen; and IVE: PTLs with dissemination to other extranodal sites.
Formalin-fixed, paraffin-embedded tissue and unstained sections were available for H&E and periodic acid Schiff (PAS) stains and immunohistochemical analysis. Immunophenotypic analysis was performed according to the standardized avidin-biotin method of Hsu et al. 32 using a pertinent commercially available antibody panel (Table 1) . Predigestion was performed with either protease or pepsin (as noted): 3 minutes with 0.05% Protease VIII (Sigma Chemical Co, St. Louis, MO, USA) in a 0.1 M phosphate buffer at pH of 7.8 at 37°C or 20 minutes with 0.04% pepsin in a 0.1 M phosphate buffer at pH 2.0 at 40°C. Antigen enhancement (recovery) was performed when appropriate by using formalinfixed, paraffin-embedded tissue treated with a buffered citric acid solution and heated for 20 minutes in a calibrated microwave oven. Following this, the sections were allowed to cool at room temperature in a citric acid buffer solution for 15 to 45 minutes before continuing the procedure. Standard positive and negative (serum) controls were used throughout.
Polymerase Chain Reaction
DNA was extracted from formalin-fixed, paraffinembedded sections as previously described. 65 t(11;14) and t(14;18) bcl-2/MBR-J H PCR assays were performed and analyzed as previously described. 2, 81 The t(14;18) bcl-2/MCR-J H assay was performed as the MBR-JH assay using AmpliTaq Gold DNA polymerase for the "hotstart" application. Bcl-2/MCR-J H primers were derived from published sequences. 55, 65 t(14;18) positive control cell lines (SUDHL-6 and SUDHL-16) were obtained from Alan Epstein, MD, PhD (USC, Los Angeles, CA, USA).
Statistical Analysis
Statistical analysis was performed on 107 cases, excluding the single case of FCL. Mean differences between groups were compared using unpaired t tests or analysis of variance (ANOVA), respectively. Tukey multiple comparison procedures were used to make twoway comparisons among groups in which ANOVA was used. Differences between observed and expected frequencies were compared using chi-square tests or Fisher's exact test when there were fewer than five patients in any subcategory. When necessary, the cases were divided into two main groups, MZBL and DLBCL, or lymphomas with a large cell component, which included both mixed DLBCL and MZBL and DLBCL without MZBL groups.
Survival analysis and a survival comparison between the two main groups of lymphomas, MZBL and DLBCL, could not be performed because only 20 patients died with disease (all with DLBCL). At least 30 cases are needed in each group to have adequate power to detect statistically meaningful differences.
For the purpose of this summary, strong findings were defined as those results for which the p value was less than 0.05 and the confidence interval did not include the null value. Weak findings were when either the p value or the confidence interval was statistically significant, but not both. Stages IIIE and IVE were combined in the analysis because of the limits of sample size.
RESULTS

Pathology
Macroscopic Findings
The lymphomas ranged in size from 0.5 to 19.5 cm in maximum dimension with a mean size of 6.9 cm (Table  2 ) without a statistically significant difference in tumor size between the three groups. Tumors that presented as a rapidly enlarging mass were, on average, larger (7.2 cm) than those tumors that presented as a mass only (6.4 cm), but this was not statistically significant (p ‫ס‬ 0.644). The tumors involved the right (n ‫ס‬ 33), left (n ‫ס‬ 23), or both lobes (n ‫ס‬ 48) of the thyroid gland. The specific lobe of the thyroid gland involved was unknown in four cases.
The tumors were described grossly as firm to soft, lobulated, multinodular to diffuse, solid or cystic masses. The cut surface was smooth or slightly bulging, pale, tan to white-gray, or red with a "fish-flesh," uniform, homogeneous to mottled appearance. Foci of hemorrhage and necrosis were frequently noted. Attachment to the 
Microscopic Findings
The lymphomas were classified into four groups: 30 MZBL, 36 mixed DLBCL and MZBL, 41 DLBCL without MZBL, and one FCL. All lymphomas were comprised of B-lymphocytes that effaced the thyroid parenchyma (Fig. 1) . Although the lymphomas varied architecturally and cytologically from case to case and within an individual case, features of lymphomas of MALTtype were identified in almost all cases.
Infiltration by the lymphoma into the perithyroidal adipose tissue and/or skeletal muscle was detected in 70% (75 of 107 cases assessable), including the case of FCL. The frequency of soft tissue infiltration increased as the quantity of the large cell component increased (p ‫ס‬ 0.027), with 58 of these 75 patients having a DLBCL. Twenty-seven cases (25%) demonstrated vascular invasion (Fig. 2 ) and all were DLBCL (p ‫ס‬ 0.0001). A variable degree of background fibrosis was detected in all cases.
Although quantity and quality varied from case to case, lymphoepithelial lesions (LEL) could be identified in most cases. LEL occurred in two forms. The first form was more common and of the usual type, characterized by neoplastic cells in variably sized nests or rounded groupings infiltrating within and between the thyroid follicular epithelium (Fig. 3) . The second type was more unique, characterized by variably sized, rounded masses of neoplastic cells that filled and distended the colloidal space of the follicles, termed by us as "MALT ball" LEL (Fig. 3) .
Lymphocytic thyroiditis was present in 94% (n ‫ס‬ 101), including the case of FCL. Lymphocytic thyroiditis usually contained reactive follicles with an absence of a dense, sheet-like effacement of the thyroid parenchyma and demonstrated both B-and T-cells areas by immunohistochemistry. Neoplastic cells occasionally colonized the germinal centers of reactive follicles in areas of lymphocytic thyroiditis. The uninvolved thyroid parenchyma contained adenomatoid nodules which were occasionally calcified and degenerated (n ‫ס‬ 22), microscopic papillary carcinoma (n ‫ס‬ 7), follicular adenoma (n ‫ס‬ 1), and follicular carcinoma (n ‫ס‬ 1).
Marginal Zone B-Cell Lymphoma of MALTType (MZBL) (n = 30). MZBL consisted of predominantly small lymphoid cells with variable proportions of centrocyte-like cells, plasma cells, lymphoplasmacytoid lymphocytes, monocytoid B-cells, and interspersed large transformed lymphocytes (Fig. 4 ). LEL were identified in all cases. In a single case, a rare large transformed cell with Reed-Sternberg-like morphology was noted, but DLBCL was not identified. The monocytoid B-cells, frequently arranged in cohesive groups, varied from small to intermediate-sized cells containing round, oval, or slightly irregular nuclei with dark chromatin and moder- (2) 5% (2) PTLs, primary thyroid gland lymphomas; LEL, lymphoepithelial lesions; MZBL, marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type; DLBCL, diffuse large B-cell lymphoma.
ate to abundant amounts of clear or pale eosinophilic cytoplasm. Cytologic atypia in monocytoid B-cells was occasionally noted and recognized by nuclear enlargement with open chromatin and conspicuous nucleoli. The monocytoid B-cells appeared epithelioid in some cases and, in others, were prominent, simulating, on lowpower magnification, a follicle center lymphoma or a small lymphocytic lymphoma with large growth (proliferation) centers.
Plasma cells were recognized in all cases, but plasmacytoid differentiation was prominent, at least focally, in 13 cases. An almost pure plasma cell population was seen in two cases. Dutcher bodies and cytoplasmic immunoglobulin (Ig) accumulations (crystalline Ig and Mott cells) were identified in 47% of cases, particularly impressive in three (Fig. 5) .
Reactive secondary lymphoid follicles, with or without follicular colonization and/or a follicular pattern, were found in 27 (90%) cases. In 11, a significant follicular architecture pattern was seen, largely attributed to follicular colonization. However, the follicular architecture was so extensive in five cases that it recapitulated a follicle center lymphoma (Fig. 6 ). A single case had the appearance of a mantle cell lymphoma (MCL) because it was nodular, was comprised of predominantly small irregular lymphocytes, and had a significant mitotic rate. Correct classification was made in these cases by identifying the characteristic histologic features of MZBL aided by immunohistochemical and molecular analysis.
Mixed DLBCL and MZBL (Marginal Zone B-Cell Lymphoma of MALT-Type With Large Cell Transformation) (n = 36). The MZBL portion had similar histologic features to those described already. The DLBCL was associated with either a transitional zone of increasing numbers of large cells intermixed with smaller neoplastic lymphocytes or occurred as an abrupt proliferation of large lymphoid cells surrounded by typical MZBL (Fig. 7 ). Variably present in each case, the large cells demonstrated centroblastic-like, immunoblastic, monocytoid B-cell, and plasmacytoid differentiation ( Fig. 8) . Scattered Reed-Sternberg-like immunoblastic cells were seen in two cases. At least focally, the areas of DLBCL in nine cases had Burkitt-like morphology consisting of sheets of intermediate-sized hyperchromatic, round neoplastic lymphocytes with mild nuclear irregularities and small amounts of basophilic cytoplasm, associated with a brisk mitotic activity, sig-
FIG. 2. Vascular invasion by malignant lymphoma.
FIG. 1. Lymphocytic thyroiditis with germinal centers (top). Malignant lymphoma effaces the thyroid parenchyma (bottom).
nificant apoptosis, and a "starry-sky" pattern on lowpower magnification.
The DLBCL component ranged from small, single or multiple foci to greater than 90% of the area of the tumor. Usually, the DLBCL component represented more than 50% of the entire lymphoma. LEL were identified in nearly every case of the mixed DLBCL and MZBL group, albeit more obvious in the MZBL areas. In the areas of DLBCL, the LEL were usually smaller, more widely separated from one another, and tended to be of the usual type (described previously). Reactive secondary follicles with or without colonization by neoplastic cells were found in 78% of mixed DLBCL and MZBL. A follicular architecture was noteworthy in 14 cases. In three lymphomas, the follicular architecture was particu- larly prominent and, in conjunction with the DLBCL areas, simulated a follicle center lymphoma, large cell with follicular and diffuse areas. However, these cases were correctly classified by the identification of features of lymphomas of MALT-type and immunohistochemical and molecular analysis.
Diffuse Large B-Cell Lymphoma Without MZBL (DLBCL Without MZBL) (n = 41). The DLBCLs were large cell lymphomas that lacked an associated MZBL. The large neoplastic cells of this group demonstrated the spectrum described above for the DLBCL component of the mixed DLBCL and MZBL group (Fig. 9) . Although less conspicuous than in the MZBL group, at least one morphologic characteristic of lymphomas of MALT-type was seen in 85% of cases (n ‫ס‬ 35) and 85% of cases were associated with lymphocytic thyroiditis. The presence of LEL, follicular colonization, monocytoid B-cell differentiation, and plasmacytoid differentiation varied in quantity and quality from case to case. 
Follicle Center Lymphoma (FCL).
The follicle center lymphoma (n ‫ס‬ 1) effaced the thyroid parenchyma with relatively uniformly sized and shaped nodules comprised of small-cleaved lymphocytes with interspersed centroblastic cells. Flattened and atretic thyroid follicular epithelium surrounded the neoplastic nodules in a circumferential manner. Marginal zone differentiation and LEL were not obvious and were presumed lacking.
Immunohistochemical Analysis
The B-cell immunophenotype of the lymphomas was confirmed by immunoreactivity with antibodies to CD20 in 105 cases and with CD79a in three cases with extensive plasmacytoid differentiation ( Table 3) . None of the lymphomas that showed a follicular pattern were bcl-2-positive, although 16% of all cases were bcl-2-reactive. Aberrant expression of CD43 occurred in 4.4% of cases tested (4 of 92). Kappa or lambda light chain restriction was demonstrated in 19% of cases (Fig. 10) . Antibodies for cytokeratin were particularly useful in highlighting LEL in areas of DLBCL (Fig. 3) . CD10 immunohistochemical analysis was performed on those cases that demonstrated a follicular pattern. Immunoreactivity was uneven with weak staining of small clusters or individual cells in the follicular areas, interpreted as residual reactive germinal center cells, or highlighted the germinal centers in areas of lymphocytic thyroiditis. The follicle center lymphoma was strongly positive for both CD10 and bcl-2. The case that simulated mantle cell lymphoma and the case that had the appearance of small lymphocytic lymphoma were negative for antibodies to CD5, CD23, CD43, and bcl-1.
Molecular Analysis
In molecular analysis, amplifiable DNA was obtained in 17 of the 25 lymphomas that demonstrated a follicular pattern, at least focally, including seven of eight cases with an extensive follicular pattern that simulated FCL. None were positive for either the t(14;18) bcl-2/MBR-JH (major break point/MBR) or the t(14;18) bcl-2/MCR-JH (minor cluster region/MCR) assays. The single case classified as follicle center lymphoma was also negative for both assays. The single case that simulated a mantle cell lymphoma was negative for the t(11;14) assay.
Clinical
Age, Gender, Signs, and Symptoms
The patients included 79 women and 29 men, with a female to male ratio of 2.7:1 (Table 4) . Their ages ranged from 28 to 95 years with a mean of 64.3 years at initial presentation. The difference in mean age at presentation for women (65.7 yrs) and men (60.5 yrs) was not statistically significant (p ‫ס‬ 0.135). Curiously, men with DLBCL without MZBL presented a decade earlier (54.9 yrs) compared with women (67.5 yrs), but this difference was also not statistically significant (p ‫ס‬ 0.508).
Clinically, all patients presented with a mass in the thyroid gland that was noticeably enlarging in 72% (n ‫ס‬ 78) of cases (Table 4) . Rapidly enlarging masses were reported more frequently in DLBCL (29% of DLBCL without MZBL, 28% of mixed DLBCL and MZBL) than in the MZBL (6.6%), yielding a statistically significant result (p ‫ס‬ 0.042). Symptoms resulting from compression/infiltration of the neck organs such as dyspnea, dysphagia, choking and/or coughing, and hemoptysis were reported in 31% of cases (n ‫ס‬ 33). Pain was also experienced. Additional symptoms were reported more frequently in enlarging tumors (37%) or rapidly enlarging tumors (33%) than in tumors that presented as a mass only (17%) and were significantly more common in DLBCL (p ‫ס‬ 0.048). As the percentage of large cell component increased, there was a greater frequency of associated symptoms resulting from compression/ infiltration of the neck structures (17% of MZBL, 25% of mixed DLBCL and MZBL, and 46% of DLBCL without MZBL).
Overall, the duration of symptoms ranged from a few days to 36 months (mean, 4 mos; Table 4 ). Whereas patients in the DLBCL without MZBL category had a slightly shorter duration of symptoms than the other groups, this difference was not statistically significant (p ‫ס‬ 0.241).
Diagnostic Investigations
Radioactive iodine uptake roentgenographic procedures were performed in the majority of patients, although a detailed radiographic narrative was available in only 52. The scans were reported to show "cold" nodules in 21 cases, diffuse low-uptake in 19 cases, and no significant abnormalities in 12 cases. Serum antibody results were available in too few cases to be meaningfully reported.
Stage
The majority of patients presented with stage IE disease (n ‫ס‬ 71, 66%; Table 5 ). An additional 27 patients presented with stage IIE (including the one follicular lymphoma), with the remaining patients presenting with stage IIIE (n ‫ס‬ 2) and stage IVE (n ‫ס‬ 8) disease. No patients with stage IE died with disease, irrespective of the histologic grade of the tumor (mean, 82.2 mos), whereas 44% of stage IIE, 100% of stage IIIE, and 75% of stage IVE patients died of their disease. MZBL patients presented with stage IE (83%) or IIE (17%) disease. All patients who presented with stage IIIE or IVE had DLBCL. When dissemination was present, either at presentation or subsequently, the most common site of involvement was lymph nodes. Cervical/perithyroidal lymph nodes were the most common nodal sites involved, usually identified at, or shortly after initial surgery, followed by mediastinal and abdominal lymph nodes. Extranodal involvement was found in 8.3% of all cases and included bone marrow (n ‫ס‬ 4), gastrointesti- nal tract (n ‫ס‬ 3), lung (n ‫ס‬ 2), and bladder and liver (one each).
Treatment and Clinical Outcome
All patients were treated with surgical excision (Table  6 ), including thyroid lobectomy or partial thyroidectomy with (n ‫ס‬ 8) or without (n ‫ס‬ 40) lymph node dissection and total thyroidectomy with (n ‫ס‬ 11) or without (n ‫ס‬ 49) lymph node dissection. In addition to surgery, adjuvant therapy was used in 75% of patients (81 of 108), commonly a combination of radiation and chemotherapy (42%; n ‫ס‬ 45). The single case classified as FCL was treated with surgery and chemotherapy only (not included in Table 6 ).
The type of treatment did not correlate with death with disease, irrespective of surgery alone (p ‫ס‬ 0.098), surgery followed by radiation (p ‫ס‬ 0.639), surgery followed by chemotherapy (p ‫ס‬ 0.117), or surgery followed by combination therapy (p ‫ס‬ 0.091).
When controlling for gender, there was no statistical association among age (p ‫ס‬ 0.508), duration of symptoms (p ‫ס‬ 0.822), or maximum size of tumor (p ‫ס‬ 0.694) and evidence of disease at last follow up. Al- 
FIG. 10. Light chain restriction for kappa (A) (lambda, B).
though patients who presented with rapidly growing tumors were more likely to die with disease (p ‫ס‬ 0.002), they did not have an increased likelihood of extrathyroidal extension (p ‫ס‬ 0.065). Overall, 70 of 108 (65%) patients were alive at last follow up, which translates into a raw survival of 60% at 5 years (14 additional patients were alive but were not yet followed for 5 yrs). However, 88 of 108 (82%) patients were alive without evidence of disease, or had died of other causes, with a mean follow up of 82.8 months. Thus, at 5 years, the disease-specific survival was 79% (74 of 94 patients who had been followed for a total of 5 years were either alive or had died of other causes). Twenty patients died with disease (mean, 21.9 mos), with most deaths (90%) occurring within 3 years of diagnosis. All had DLBCL. Of particular interest in our series: if the patient was alive at last follow up, they were disease-free. Eighteen patients died without evidence of disease of unrelated causes, including 7 patients with MZBL, 7 with mixed DLBCL and MZBL, and 4 with DLBCL without MZBL. There was a statistically significant difference in survival between those patients who died with disease and those patients who were alive or had died of unrelated causes (p ‫ס‬ 0.0001). The diseasespecific 5-year survival rates by category were: MZBL, 100%; mixed DLBCL and MZBL, 78%; and DLBCL without MZBL, 71%, whereas the overall 5-year survival rates by category were slightly shorter as a result of intercurrent, but unrelated, deaths (MZBL, 77%; mixed DLBCL and MZBL, 47%; and DLBCL without MZBL, 54%). The patient with the tumor classified as FCL was alive without disease, almost 4 years after diagnosis.
All patients who died with disease presented with stage IIE or higher disease and had DLBCL. Stage of disease was strongly associated with death with disease. The strong statistical significance is the result of the difference between stage IE and stage IIE groups (p ‫ס‬ 0.0001; Table 7 ). Statistical difference between stage IIE and combined stage IIIE and stage IVE groups was not significant (p ‫ס‬ 0.133).
The presence of a DLBCL was strongly associated with death with disease and DLBCL had a worse clinical Perithyroidal soft tissue invasion was significantly associated with death with disease (p ‫ס‬ 0.025), as 18 of 20 patients (90%) who died of disease had lymphomas that demonstrated perithyroidal extension. Likewise, the presence of vascular invasion was significantly associated with death with disease (p ‫ס‬ 0.005). Furthermore, vascular invasion was only identified in DLBCL, and those who died with disease had stage IIE or higher disease. Patients with lymphomas that demonstrated abundant apoptosis (p ‫ס‬ 0.003) and high mitotic rates (p ‫ס‬ 0.022), histologic features more often found in the DLBCL (p ‫ס‬ 0.0001), were significantly more likely to die with disease (Table 7) . Although tumor necrosis was significantly more likely to be present in the DLBCL (p ‫ס‬ 0.0001), this histologic finding was not associated with death with disease (p ‫ס‬ 0.138). Similarly, grade of fibrosis was not associated with death with disease (p ‫ס‬ 0.123). There was no significant difference in the number of sections examined per case between the tumor categories (p ‫ס‬ 0.664).
DISCUSSION
PTLs typically occur in middle-to older-aged individuals in the setting of lymphocytic thyroiditis with a predilection for females. Patients present with a mass in the thyroid, usually noticeably enlarging, and commonly have symptoms related to compression of neck structures by the tumor. With radioisotopic 131 I scanning, a cold nodule or areas of decreased uptake are common.
PTLs demonstrate considerable diversity in architecture and cytology, not only from case to case, but within the same case. Although isolated T-cell PTLs have been reported, 1, 54, 59, 69, 82 all cases in this study were B-cell lymphomas. Barring the single FCL, they fell into three groups: MZBL, mixed DLBCL and MZBL, and DLBCL without MZBL. Many of our cases (71%) contained a DLBCL element, paralleling the findings in the literature. 9, 11, 13, 14, [23] [24] [25] 34, 36, 41, 42, 51, 52, 54, 59, 64, [69] [70] [71] [75] [76] [77] [78] Conversely, almost half (47%) of our tumors that contained a DLBCL contained a MZBL, to which the term mixed DLBCL and MZBL was applied (in keeping with terminology of the REAL and proposed WHO classifications). The small and large cell components varied in proportion from case to case, requiring evaluation of several slides to recognize the mixture. Random microscopic foci of DLBCL or small areas of MZBL could be easily missed on cursory examination or with limited sampling. Mixed DLBCL and MZBL, previously reported in other extranodal sites 17, 22, 30, 46, 60, 61, 66 as well as in the thyroid gland, 34, 45, 59, 69 seem to represent approximately one third of all thyroid lymphomas, similar to our findings (33% of all cases). Could the mixed DLBCL and MZBL cases represent de novo mixed small and large cell presentations? Absolutely, but the occasional focal nature of the components, areas of transition between the two histologies, and the clinical presentation of a rapidly enlarging mass lend support to the transformation theory (large cell transformation). Furthermore, many patients with PTLs have a history of sustained thyroid enlargement or goiter before the presentation of a mass or rapid enlargement of the gland, suggesting that there may have been a pre-existing MZBL before the development of DLBCL (large cell transformation). 3, 5, 6, 9, 11, 19, 23, 42, 71, 78 In fact, a study of a few patients with a history of persistent goiter retrospectively had MZBL that went undetected. 34 Moreover, immunohistochemical and molecular studies characterizing mixed DLBCL and MZBL in the thyroid and stomach lend further support to the transformation theory. 17, 22, 30, 60, 61 Although characteristics of lymphomas of MALTtype were more obvious in MZBL, they were also found in the areas of DLBCL. Barring lymphocytic thyroiditis, LEL were the most common characteristic identified in the DLBCL, accentuated with CD20 and cytokeratin stains. Although there were notable exceptions, the neoplastic large lymphocytes were more destructive and invasive. Consequently, the LEL were typically fewer, smaller, and more inconspicuous than in the MZBL areas and were most often of the usual type. In our series, the "MALT ball" type of LEL, seen most often in MZBL, were unique and seemed specific for malignancy, a feature that has been suggested by others. 3, 5, 9, 19, 31, 56 We attribute the differences in quality and quantity of LEL between the MZBL and DLBCL components to the tumor's degree of differentiation. 38 In a large cell lymphoma, the presence of a MZBL and/or LEL has been used by some authors to classify a lymphoma as a lymphoma of MALT-type. 30, 59 While LEL of the usual type are not specific and can be seen in benign lymphoid proliferations involving the thyroid such as Hashimoto's (lymphocytic) thyroiditis, 31, 47, 50 LEL formed by either small or large B-lymphocytes which diffusely efface the thyroid parenchyma support a lymphoma of MALT-type in the thyroid. In other words, a DLBCL in the thyroid gland that demonstrates LEL, whether or not there is an accompanying MZBL, supports that it is a lymphoma of MALT-type. However, because we think the ability of a lymphoma of MALT-type to form LEL in the thyroid is affected by its degree of differentiation, a lack of prominent LEL should not preclude the same designation.
Lymphocytic thyroiditis is almost certainly a requisite for the development of lymphoma in the thyroid. The few cases (<7%) that did not have documented lymphocytic thyroiditis may have been either inadequately sampled or the lymphoma may have completely obliterated any residual thyroid tissue. Furthermore, the chronicity of the disease process was supported by the presence of atrophy of the thyroid parenchyma and the presence of fibrosis, often of a moderate to severe degree, in all cases.
In this study, FCL, as a PTL, is uncommon when defined by the clinicopathologic features typical of those arising in nodal sites. Of 108 cases, we made this diagnosis in only one case, based on histologic and immunohistochemical findings. The FCL in our series demonstrated a prominent follicular architecture, lacked definitive features of a MZBL (although there was lymphocytic thyroiditis), and was immunoreactive for CD10. Before the understanding of the MALT concept, a significant proportion of PTLs was thought to be of follicle center origin. [3] [4] [5] 8, 9, 11, 19, 23, 28, 48, 50, 52, 54, 56, 70 It is well known that extensive colonization of the germinal centers of reactive follicles by neoplastic marginal zone cells in MZBL can resemble follicle center lymphoma. 34, [36] [37] [38] 46 The follicular pattern seen in 25 of our cases could be attributed to this phenomenon, a finding similar to that of other authors. 3 In many of these (n ‫ס‬ 17), features of MZBL were easily identified, raising little question as to their subclassification. However, we were impressed how eight cases closely resembled FCL. On closer observation, despite a prominent nodular architecture, marginal zone differentiation and LEL could be distinguished. Additionally, all were negative for bcl-2 and CD10 by immunohistochemical analysis and were negative for t(14;18) molecular assays. A study specifically addressing this issue analyzed nine MZBL of the thyroid that demonstrated a prominent follicular pattern. None of these cases were immunoreactive for CD10 (on frozen instead of paraffin-embedded, formalin-fixed tissue) or showed evidence of a t(14;18) using polymerase chain reaction on DNA from fresh and/or paraffinembedded tissue. 37 Similar findings, using immunohistochemical and molecular techniques, have been reported in gastrointestinal tract MZBL which demonstrated a follicular pattern. 39, 58 From a clinical perspective, the tumors in our study were not characteristic for FCL, almost always presenting with low-stage disease without bone marrow involvement. Only one patient presented with high-stage disease (IVE), with the lymphoma identified in the bladder and gastrointestinal tract, organs that can be considered part of the "MALT axis." Furthermore, the outcomes were not characteristic of FCL. Of the patients with a follicular pattern, only two patients died with disease less than a year after presentation (mixed DLBCL and MZBL, initially stage IE disease). The remaining patients were either alive (n ‫ס‬ 21) or had died (n ‫ס‬ 2) of other causes with no evidence of disease at last follow up. Our only case of FCL did not yield positive t(14;18) assays. However, the negative t(14;18) assay could be explained by a false-negative result. On the other hand, there is room for doubt about our classification of this case, because the patient presented with stage IIE disease, had lymphocytic thyroiditis, and is alive without evidence of disease at last follow up, 46.5 months after presentation.
It is our supposition that most PTL are lymphomas of MALT-type that have a highly variable cytomorphologic appearance and range from MZBL to "DLBCL of MALT-type." However, they can simulate "non-MALTtype" lymphomas. 6 The architectural heterogeneity of lymphomas in the thyroid may depend on the mutational events leading to the development of the neoplastic clone. It is well known that centrocyte-like lymphocytes are common components of the typically cytologically heterogeneous MZBL. Is it possible that the neoplastic clone of some lymphomas that develop out of MALT favors follicle center or mantle zone-like differentiation over monocytoid B-cell or plasma cell lines? This theory is supported by the recent description of a nodular variant of marginal zone B-cell lymphoma that can simulate follicle center or even a mantle cell lymphoma. 15 Although further study is necessary, we think, in the thyroid, FCLs are uncommon and MCLs are exceptional. Because appropriate treatment and prognostic implications depend on accurate classification, we recommend that the diagnosis of a primary FCL or MCL in the thyroid be made only when the tumor arises primarily in the thyroid and there is supportive immunohistochemical and/or molecular evidence.
Plasma cells and plasmacytic differentiation were common in our PTL. It is not difficult to suggest as others have 3, 33, 36 that cases previously report-ed as extramedullary plasmacytomas of the thyroid 4, 7, 9, 12, 18, 19, 23, 44, 54, 57, 68, 80 represent MZBL with extreme plasma cell differentiation. Although a few of our MZBL cases could have been called extramedullary plasmacytomas (EMP) by some pathologists, studies support that EMP are different entities from solitary plasmacytomas of the bone (SPB) and multiple myeloma (MM) (neoplasms arising from marrow cells) and that EMP are probably MZBL with extensive plasma cell differentiation with origin from MALT. 20, 33, 53, 79 This theory is based on the numerous clinicopathologic similarities that exist between EMP and MZBL. In our study, we found that the quantity of the plasma cell component varied greatly, as did other histologic characteristics of MZBL, from one case to the next, thus indicating a disease with a wide histologic spectrum. Although not all characteristics of MZBL were seen in our plasma cellpredominant MZBL cases, many features could be identified. These findings are similar to a recent study addressing this issue in which features of MZBL could be identified in five cases from various non-thyroidal extramedullary sites that were diagnosed as EMP originally but thought to represent MZBL with extensive plasma cell differentiation. 33 Although EMP in the thyroid could represent different entities from plasma cell predominant MZBL, mounting evidence appears to support otherwise. Lastly, plasma cell dyscrasias such as MM could involve the thyroid secondarily, but clear-cut evidence fulfilling established diagnostic criteria to support this unusual event (that is, atypical plasma cell infiltrate of the marrow, lytic bone lesions, monoclonal gammopathy) would be required to support this interpretation.
The plasma cells in a MZBL of the thyroid may be reactive and part of the lymphocytic thyroiditis. This may account for our inability to demonstrate monoclonality with immunohistochemistry in a number of our cases. However, CD79a immunoreactivity was helpful in confirming the B-cell immunophenotype of cases that were negative for L26 because of plasmacytoid differentiation. While there may be true T-cell lymphomas of MALT origin of the thyroid, 38 because UCHL-1 can be expressed by some B-cell lymphomas, as observed in our study, it should not be used alone. The use of more specific T-cell markers such as CD3 and CD5 is recommended.
Reed-Sternberg-like cells are known to occur in a wide variety of lymphoma subtypes and in reactive lymphoid proliferations, so it is not surprising that a few of our cases, like those in the literature, 14, 52, 80 contained these cells. However, we could not verify the claims of others that report primary thyroid Hodgkin's lymphoma in our series. 19, 26, 42, 49, 76 It is difficult to compare our 5-year disease-specific survival of 79% to the wide range of 35% to 79% reported in the literature 3, 5, 11, 13, 14, 19, 24, 41, 42, 45, 48, 51, 52, 54, 59, 62, 64, [69] [70] [71] [72] [74] [75] [76] [77] 80 because of differences in population size, study design, lymphoma classification used, treatment modalities used, and statistical analyses used. As expected, 14, 19, 76 ,80 a number of clinical and histologic findings were predictive of patient outcome (Table 7) , although the relationship of stage of disease and histologic grade are certainly interrelated. Patients who presented with enlarging tumors or symptoms of compression of neck organs were more likely to die with disease, as expected. 13, 41, 48, 69, 71, 76 However, age at presentation, gender, and size of the tumor were not prognostic markers, contrary to other studies. 5, 41, 43, 48, 71, 75, 76 The majority (91%) of our patients presented with stage IE or IIE disease, analogous to other reports. 5 80 We realize that differences in staging modalities and variability in treatment regimens can affect findings. However, none of the patients with stage IE, irrespective of histologic grade, died with disease. Therefore, because of prognostic implications, accurate staging is important.
It is difficult to separate clinical stage and histologic findings as prognostic indicators, because these parameters are intimately interrelated. In our study, only patients with DLBCL (mixed DLBCL and MZBL and DLBCL without MZBL) presented with advanced stage (stage IIIE or IVE) and/or had a poor outcome. All MZBL presented with lower stage disease (most stage IE) and none died with disease. Although evidence to support histology as a prognostic indicator varies in the literature, in our study, the lymphomas, when divided into two main subgroups MZBL and DLBCL, demonstrated a strong statistical association with death with disease (p ‫ס‬ 0.002). Therefore, the distinction between MZBL and DLBCL in the thyroid is important and clinically significant. Distinction between mixed DLBCL and MZBL and DLBCL without MZBL categories appears not to be important. However, analysis of a larger series of cases may be necessary to confirm this conclusion.
Because the majority (71%) of our patients with DLBCL had a favorable outcome, we studied additional histologic factors to see if they had an influence on clinical behavior. In our series, presence of vascular invasion, abundant apoptosis, high mitotic rate, and perithyroidal soft tissue invasion were significant histologic prognostic indicators. Vascular invasion 5, 19, 56 and perithyroidal invasion 11, 14, 19, 42, 56, 76, 78, 80 have been demonstrated to be indicators of poor clinical outcome in the past. There is no study, to our knowledge, that has demonstrated apoptosis as a significant prognostic factor. Although all of these histologic features were significantly more characteristic of DLBCL (high mitotic activity, frank necrosis, and abundant apoptosis; p ‫ס‬ 0.0001), with the exception of vascular invasion, these histologic features could be identified without adverse effects on clinical outcome in the MZBL group. However, there may be use in seeking these histologic features, particularly in DLBCL, because their presence may portend a greater risk of recurrence and/or dying of disease.
As expected, chemotherapy was used in a greater percentage of the DLBCL, but it is difficult to accurately determine the impact of a single therapeutic modality on patient survival when a wide variety of different treatment modalities were applied in an uncontrolled manner. Therefore, we cannot extrapolate our findings to clinical application. However, authors have documented a significant relapse rate of PTLs at distant sites, attributed to treatment failure. 13, 21, 36, 41, 63, [75] [76] [77] Whereas a number of studies have reported improved survival with tumor debulking and local control of the tumor, 13, 41, 67, 75, 76 a more favorable patient outcome seems to follow the use of combined adjuvant therapy, 51, 63, 71, 75 even without tumor debulking. Our excellent overall survival rates may be related to a combination of good local control of the tumor through the use of surgery and radiation therapy and control of disseminated disease, undetected at presentation, with chemotherapy (57% of patients), despite a lower stage of disease at presentation. Chemotherapy may have treated undetected occult disseminated disease in our patients and protected against recurrence, particularly for those patients with DLBCL. Further, recent improvements in radiotherapeutic techniques and better chemotherapy regimens may account for the better survival in our patients compared with patients in earlier studies.
In conclusion, we studied 108 PTL using recent concepts. PTLs typically occur in middle-to older-aged persons and have a predilection for females. Virtually all PTLs are lymphomas of MALT-type, arising as neoplastic transformations from MALT in the form of lymphocytic thyroiditis. In keeping with the current terminology, most PTLs can be classified as MZBL or DLBCL (DLBCL of MALT-type). Mixed DLBCL and MZBL are common. Because the histology of PTL varies tremendously and can sometimes simulate other "non-MALTtype lymphomas," specifically FCL, familiarity with the various patterns of PTL will prevent misclassification and clinical confusion. The overall clinical outcome for PTL is favorable with appropriate management, but recurrence and death from disease do occur. The prognosis of PTL is dependent on both histologic findings and clinical stage, with patients having MZBL and stage IE disease yielding the best prognosis and those with DLBCL or greater than stage IE disease having the greatest potential for a poor outcome. Further study is needed to determine the occurrence and frequency of PTLs of "non-MALT-type." ᮀ
